Royalty Pharma earnings, Revenue miss in Q3

  • Investing.com
Royalty Pharma earnings, Revenue miss in Q3

Investing.com - Royalty Pharma reported on Tuesday third quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.

Royalty Pharma announced earnings per share of $0.24 on revenue of $573M. Analysts polled by Investing.com anticipated EPS of $0.71 on revenue of $584.92M.

Royalty Pharma shares are down 35% from the beginning of the year and are trading at $42.48 , down-from-52-week-high.

Royalty Pharma shares gained 0.27% in intra-day trade the report.

Royalty Pharma follows other major Healthcare sector earnings this month

Royalty Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, compared to forecasts EPS of $5.43 on revenue of $80.52B.

J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, compared to forecast for EPS of $2.52 on revenue of $23.46B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles